Traductor

28 September 2010

Bristol-Myers buy of ZymoGenetics clears hurdle

Bristol-Myers Squibb Co. /quotes/comstock/13*!bmy/quotes/nls/bmy (BMY 27.90, +0.30, +1.09%) said Tuesday the mandatory Hart-Scott-Rodino waiting period for its offer to buy ZymoGenetics Inc. /quotes/comstock/15*!zgen/quotes/nls/zgen (ZGEN 9.74, +0.00, +0.02%) has expired. Bristol-Myers on Sept. 10 launched an offer to buy ZymoGenetics for $9.75 a share, or about $735 million, net of cash, after the two companies inked a merger agreement on Sept. 7.


**Published in "Market Watch"

No comments:

Post a Comment

CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies

Copyright © Noticia de Salud